Previous 10 | Next 10 |
Caladrius Biosciences, Inc. (CLBS) Q1 2019 Results Earnings Conference Call May 09, 2019, 04:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Josep...
Caladrius Biosciences (NASDAQ: CLBS ): Q1 GAAP EPS of -$0.44. Cash and equivaents of $38.4M. Press Release More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment in late 2019 Cash on hand projected to support existing programs through 2Q2020 ...
BASKING RIDGE, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the pote...
BASKING RIDGE, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the pote...
Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal...
BASKING RIDGE, N.J., April 03, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the po...
Caladrius Biosciences, Inc. (CLBS) Q4 2018 Earnings Conference Call March 14, 2019 16:30 ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Pete Enderlin -...
Caladrius Biosciences (NASDAQ: CLBS ): Q4 GAAP EPS of -$0.36. More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, NJ / ACCESSWIRE / March 14, 2019 / Caladrius Biosciences, Inc. (NASDAQ: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative ...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...